Bicocca Open Archive

Logo unimib boa
TETTAMANTI, SARAH
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.455
AS - Asia 2.530
EU - Europa 2.035
SA - Sud America 379
AF - Africa 79
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.490
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.336
SG - Singapore 837
IT - Italia 725
CN - Cina 498
HK - Hong Kong 342
VN - Vietnam 328
BR - Brasile 300
DE - Germania 230
RU - Federazione Russa 230
IE - Irlanda 189
SE - Svezia 136
GB - Regno Unito 114
IN - India 111
FR - Francia 96
CA - Canada 78
ID - Indonesia 67
FI - Finlandia 55
KR - Corea 48
BD - Bangladesh 40
ES - Italia 40
JP - Giappone 40
IQ - Iraq 38
PL - Polonia 38
ZA - Sudafrica 35
NL - Olanda 34
TR - Turchia 31
UA - Ucraina 31
PK - Pakistan 29
MX - Messico 25
AT - Austria 24
AR - Argentina 23
IR - Iran 20
CH - Svizzera 19
PH - Filippine 17
SA - Arabia Saudita 16
BE - Belgio 15
DK - Danimarca 13
VE - Venezuela 11
CO - Colombia 10
EC - Ecuador 10
LT - Lituania 9
IL - Israele 8
NP - Nepal 8
RO - Romania 8
TW - Taiwan 8
AU - Australia 7
EG - Egitto 7
RS - Serbia 7
CL - Cile 6
JM - Giamaica 6
KZ - Kazakistan 6
MA - Marocco 6
PE - Perù 6
UZ - Uzbekistan 6
CZ - Repubblica Ceca 5
NO - Norvegia 5
PY - Paraguay 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
CI - Costa d'Avorio 4
DZ - Algeria 4
JO - Giordania 4
KE - Kenya 4
LB - Libano 4
MY - Malesia 4
UY - Uruguay 4
AL - Albania 3
AO - Angola 3
BO - Bolivia 3
ET - Etiopia 3
NZ - Nuova Zelanda 3
PA - Panama 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
AM - Armenia 2
DO - Repubblica Dominicana 2
HR - Croazia 2
MN - Mongolia 2
MU - Mauritius 2
OM - Oman 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AG - Antigua e Barbuda 1
AZ - Azerbaigian 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BZ - Belize 1
CG - Congo 1
CR - Costa Rica 1
CY - Cipro 1
GA - Gabon 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MO - Macao, regione amministrativa speciale della Cina 1
NG - Nigeria 1
Totale 8.485
Salva come PNG Salva come JPEG
Città #
Singapore 497
Ashburn 431
Ann Arbor 429
Hong Kong 319
San Jose 288
Milan 238
Chandler 186
Dublin 183
Frankfurt am Main 133
Los Angeles 115
Fairfield 114
New York 111
Ho Chi Minh City 109
Beijing 83
Wilmington 78
Hanoi 76
Seattle 76
Dallas 74
Hefei 72
Houston 67
Santa Clara 64
Woodbridge 62
Chicago 61
The Dalles 58
Jakarta 51
Shanghai 48
Cambridge 47
Bergamo 42
Council Bluffs 40
Denver 39
Seoul 38
Princeton 37
São Paulo 37
Tokyo 34
Buffalo 33
Montreal 33
Munich 32
Helsinki 29
Dearborn 28
Orem 26
Johannesburg 25
Lauterbourg 25
Warsaw 24
Lissone 22
Nanjing 22
Moscow 20
Poplar 17
Stockholm 17
London 16
Paris 16
Altamura 15
Atlanta 15
Brussels 15
Mumbai 15
Lahore 14
Lappeenranta 14
Rome 14
Toronto 14
Turin 14
Vienna 14
Zurich 14
Baghdad 13
Brooklyn 13
Haiphong 13
Lawrence 13
Manchester 13
Monza 13
Da Nang 12
Desio 12
Hyderabad 12
Jacksonville 12
Nuremberg 12
Borgomanero 11
Genoa 11
Andover 10
Ankara 10
Carate Brianza 10
Carrboro 10
Cinisello Balsamo 10
Seregno 10
Boston 9
Chennai 9
Dhaka 9
Phoenix 9
Turku 9
Barnet 8
Bologna 8
Brasília 8
Fremont 8
Hải Dương 8
Jeddah 8
Kent 8
Naples 8
New Delhi 8
Pune 8
Wroclaw 8
Amsterdam 7
Belo Horizonte 7
Bắc Ninh 7
Florence 7
Totale 5.261
Salva come PNG Salva come JPEG
Nome #
Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies 429
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 423
Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System 413
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia 401
MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor (MIF) as a Possible Indicator of Response to Therapy in Membranous Nephropathy 385
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia 376
Transposon-Based CAR T Cells in Acute Leukemias: Where are We Going? 349
CXCR4-MODIFIED CD33.CAR-CIK WITH ENHANCED BONE MARROW HOMING IN ACUTE MYELOID LEUKEMIA 347
Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the Acute Myeloid Leukemia burden 288
Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use 279
Unlocking the Heterogeneity in Acute Leukaemia: Dissection of Clonal Architecture and Metabolic Properties for Clinical Interventions 276
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation 269
Overexpression of CXCR4 receptor on CD33.CAR-CIK cells enhances the control of the Acute Myeloid Leukemia burden 266
Catch me if you can: how AML and its niche escape immunotherapy 252
Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia 246
IL3-zetakine combined with a CD33 costimulatory receptor as a Dual CAR approach for safer and selective targeting of AML 242
Cellule CD33.CAR-CIK ingegnerizzate per co-esprimere il recettore CXCR4 al fine di aumentare la capacità di migrazione all’interno della nicchia midollare nella leucemia mieloide acuta 240
Overexpression of CXCR4 Enhances the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia 239
Combining the expression of CD33.CAR and CXCR4 to augment CAR-CIKs homing to bone marrow niche and leukemic stem cell eradication in acute myeloid leukemia 237
Optimized GMP-grade production of non-viral Sleeping Beauty-generated CARCIK cells for enhanced fitness and clinical scalability 236
Update on: proteome analysis in thyroid pathology - part II: overview of technical and clinical enhancement of proteomic investigation of the thyroid lesions 235
Combining the Expression of CD33.CAR and CXCR4 to Increase CAR-CIK Cell Homing to Bone Marrow Niche and Leukemic Stem Cell Eradication in Acute Myeloid Leukemia 231
CARs are sharpening their weapons 230
Carcik-CD19 Cells Expand In Vivo Toward a CD8+ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response 225
Generation of CIK cells co-expressing CXCR4 and CD33.CAR with improved homing and antitumor activity for AML 223
Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche 213
Improving Bone Marrow Homing and Persistence of CD33.CAR-CIK Cells By Overexpression of a Gain-of-Function Variant of CXCR4 to Increase Efficacy in Acute Myeloid Leukemia 210
Ingegnerizzazione di cellule CD33.CAR-CIK con una variante gain-of-function del recettore CXCR4 per aumentarne migrazione e persistenza nella nicchia midollare 195
Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies 188
The management of haemoglobin interference for the MALDI-MSI analysis of in-vivo thyroid biopsies 178
Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab 172
Acute Myeloid Leukemia (AML) immunotherapy: development of TIM3-CD33 targeted Dual CAR CIK cells for eradication of LSCs in the bone marrow niche 167
Advancing CIK cell immunotherapy: highlights from the second international conference on DC-CIK and CAR-CIK approaches 25
Totale 8.685
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.157
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.157
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021113 0 0 0 0 0 0 0 0 0 43 29 41
2021/2022335 23 33 22 18 20 18 11 15 24 32 24 95
2022/2023703 91 164 69 65 16 93 19 51 49 4 58 24
2023/2024723 31 29 45 59 72 171 117 46 59 19 14 61
2024/20251.639 62 111 134 65 109 103 125 74 150 247 165 294
2025/20264.113 569 249 315 617 618 236 665 154 308 382 0 0
Totale 8.685